Intravenous recombinant tissue plasminogen activator is a highly effective treatment for acute ischemic stroke, but routine provision is challenging. We compared the activity, safety and response times of five service configurations: local services, redirection of selected or all suspected stroke patients by emergency medical services (EMS) to stroke centers and the use of telemedicine with and without secondary transfer to a stroke center. In total, 59 relevant service descriptions were identified. Pooled treatment rates (mean ± standard deviation [SD]) per 100 confirmed stroke patients were: local service design, 2.5 ± 2.5 (n = 21417); EMS redirection of only patients potentially eligible for thrombolysis, 3.9 ± 1.2 (n = 1872); EMS redire...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...
International audienceBackground:In the context of the development of telemedicine in France to addr...
OBJECTIVES: To evaluate the impact of the Victorian Stroke Telemedicine (VST) program during its fir...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator...
Background and Purpose—Telestroke networks offer an opportunity to increase tissue-type plasminogen ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Purpose: We report the Belgian results of the Safe Implementation of Thrombolysis in Stroke Internat...
Objectives: Barriers to intravenous (IV) tissue plasminogen activator (tPA) use in ischemic stroke i...
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evi...
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is th...
Objectives: To evaluate the impact of the Victorian Stroke Telemedicine (VST) program during its fir...
Background and Purpose—Systemic thrombolysis represents the main proven therapy for acute ischemic s...
Background Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute ischem...
Stroke is the fourth leading killer in the United States and a leading cause of adult long-term disa...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...
International audienceBackground:In the context of the development of telemedicine in France to addr...
OBJECTIVES: To evaluate the impact of the Victorian Stroke Telemedicine (VST) program during its fir...
Background: Thrombolytic therapy with recombinant tissue plasminogen activator (rt-PA) is licensed f...
BACKGROUND AND AIMS: Thrombolytic therapy with intravenous recombinant tissue plasminogen activator...
Background and Purpose—Telestroke networks offer an opportunity to increase tissue-type plasminogen ...
Background and Purpose-Thrombolysis with intravenous recombinant tissue plasminogen activator is an ...
Purpose: We report the Belgian results of the Safe Implementation of Thrombolysis in Stroke Internat...
Objectives: Barriers to intravenous (IV) tissue plasminogen activator (tPA) use in ischemic stroke i...
Background: Thrombolysis using intravenous (IV) tissue plasminogen activator (tPA) is one of few evi...
What is known and Objective: Thrombolysis using intravenous tissue plasminogen activator (tPA) is th...
Objectives: To evaluate the impact of the Victorian Stroke Telemedicine (VST) program during its fir...
Background and Purpose—Systemic thrombolysis represents the main proven therapy for acute ischemic s...
Background Intravenous thrombolytic therapy (IVT) with tissue plasminogen activator for acute ischem...
Stroke is the fourth leading killer in the United States and a leading cause of adult long-term disa...
Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible pat...
International audienceBackground:In the context of the development of telemedicine in France to addr...
OBJECTIVES: To evaluate the impact of the Victorian Stroke Telemedicine (VST) program during its fir...